Anixa Biosciences, Inc. (ANIX) Cash Flow Statement

The persistent divergence between net losses and operating cash outflows indicates that the company's accounting results are heavily impacted by non-cash charges. Investors should interpret this as a signal that the headline net loss figure may understate the actual cash requirements needed to sustain the current clinical development trajectory.

The lack of positive free cash flow is a structural characteristic of the company's pre-commercial status. This trend suggests that the firm remains entirely dependent on external financing to bridge the gap between its research-heavy cost structure and the lack of incoming commercial revenue.

These fluctuations suggest that management is likely managing cash outflows by timing payments to clinical partners and academic institutions. Such volatility warrants further investigation, as it may indicate that the company is stretching payables to preserve its limited cash runway during periods of high clinical activity.